Ranolazine in Ischemic Cardiomyopathy
Ranolazine in Ischemic Cardiomyopathy
Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and
 shortness of breath despite conventional medical therapy and/or revascularization. The
 purpose of this study is to determine the efficacy of taking Ranexa versus placebo in
 patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional
 medical therapy and/or percutaneous revascularization.
Inclusion Criteria:

 1. Ischemic cardiomyopathy patients on optimal medical treatment. Optimal medical
 treatment is defined as the continued symptoms of chest pain or dyspnea despite
 treatment with 2 antiischemic agents (beta blockers, CCB or nitrates). Unless
 contraindicated, all cardiomyopathy patients should be treated with a beta blocker and
 an ACEI/ARB.

 2. Anginal chest pain or dyspnea

 3. Documentation of non treatable or optimally treated coronary artery disease

 4. Ejection Fraction of less than or equal to 40%

 Exclusion Criteria:

 1. Less than 18 years of age

 2. Pregnant or breast feeding

 3. Patients with non ischemic cardiomyopathy